GL:NYSEGlobe Life Inc. Analysis
Data as of 2026-09-27 - not real-time
$167.04
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
At $167.04, Globe Life Inc. shows no decisive moving-average alignment, leaving the trend neutral. It has lost 7.5% over the past 30 days. RSI sits at 34.9, which reads as approaching oversold, and MACD momentum is bearish. Watch $166.05 as support and $177.00 as the nearer resistance level.
On valuation the read is undervalued — earnings multiple of 11.1 versus a 15.6 sector average, below the peer group. The average analyst target implies 16.1% above today's level. Revenue is growing at 8.0% on a 19.6% profit margin. The 0.79% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 18.3%, a beta of 0.29 and a maximum drawdown of 10.2%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 6/10 long-term conviction.
On valuation the read is undervalued — earnings multiple of 11.1 versus a 15.6 sector average, below the peer group. The average analyst target implies 16.1% above today's level. Revenue is growing at 8.0% on a 19.6% profit margin. The 0.79% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 18.3%, a beta of 0.29 and a maximum drawdown of 10.2%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 6/10 long-term conviction.
Top Market Events
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in...Die Globe-Life-Aktie notierte am 21.09.2026 bei 139,19 USD an der NYSE. Die Marktkapitalisierung lagDie Globe-Life-Aktie schloss am 18.09.2026 an der NYSE bei 173,42 USD und liegt damit nahe dem Analy
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- Trading above the 200-day average of 156.68
- MACD momentum is negative
- 30-day price change of -7.5%
Medium Term
1–3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 11.1 versus sector average of 15.6
- Trading above the 200-day average of 156.68
- Analyst targets imply +16.1% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- P/E of 11.1 versus sector average of 15.6
- Analyst targets imply +16.1% versus the current price
- Profit margin of 19.6% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth8.00%
Profit Margin19.58%
P/E Ratio11.1
ROE20.94%
ROA3.36%
Debt/Equity55.67
P/B Ratio2.1
Op. Cash Flow$1.4B
Free Cash Flow$1.2B
Industry P/E15.6
Technical Analysis
TrendNeutral
RSI34.9
Support$166.05
Resistance$177.00
MA 20$171.70
MA 50$176.14
MA 200$156.68
MACDBearish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Fair Value$215.50
Target Price$193.91
Upside/Downside16.09%
GradeUndervalued
TypeBlend
Dividend Yield0.79%
Risk Assessment
Beta0.29
Volatility18.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.